INTRODUCTION

S
ystemic sclerosis (SSc) is a dysimmune disorder of connective tissue characterized by disregulation of endothelial function and progressive tissue fibrosis. Although many studies have been carried out the pathogenesis of SSc is an issue still elusive. In a pioneer paper Murrel DF suggested oxidative stress (OS) as the keystone linking altered immune tolerance, endothelial injury and pro-fibrotic phenotype of SSc (1) . In the last decade, this intriguing hypothesis has been strengthened by several firm evidences obtained at a cellular and molecular level. OS refers to a condition characterized by an imbalance in prooxidants and antioxidants, which results in damage to macromolecules (protein, lipids Reumatismo, 2009; 61(2) paired in SSc patients consistently with the evidence of reduced reserve of ascorbic acid, selenium (5), α-tocopherol and carotene (10) regardless of appropriate dietary intake (11) . Therefore targeting OS may have a favorable impact on the clinical features and progression of SSc. Intriguingly, two drugs effective in the treatment of some clinical SSc features such as calcium channel blockers and ACE-inhibitors possess an interesting activity in reducing OS due to inhibitory effect on the activity of ROS producing enzymes (12, 13) . Unfortunately, interventional trials with antioxidant agents designed to reduce OS in SSc have given conflicting and disappointing results (14) (15) (16) (17) . Iloprost, a stable prostacyclin-mimetic drug, is widely prescribed to treat vascular features of SSc (Raynaud's phenomenon, digitals ulcers and pulmonary arterial hypertension) on the grounds of its well known vasodilatory and antiaggregant effects. Beside these actions, Iloprost appears to have also an antioxidant effect which substantially adds on to the spectrum of his "non conventional" (e.g. antifibrotic and angiogenetic) actions. Yet molecular pathways underlying this putative property have been not fully dissected, nonetheless several reports offer the clues to suggest them.
NADPH Oxidase (Nox) and MAPK pathways in SSc ROS are physiological "inescapable" byproduct of cellular metabolism and derive from multiple cellular sources, including mitochondrial electron transport and xanthine oxidase. In most of cellular types the largest amount of ROS is generated by Nox, a heme-containing multi-subunit enzyme which catalyze the production of O 2 •− (which plays a role in phagocitic cells against infections owing to its bactericidal activity). (26) . Once generated, ROS transduce the proliferative and fibrotic signals of PDGF and TGF-β by turning on the mitogen activated kinases (MAPK) cascade. Member of this latter family are extracellular signal-regulated kinases 1 and 2 (ERK1/2), Jun NH2-terminal kinase (JNK) and p38 kinase. Thus the proper transmission of growth signal rely on the action of ROS as signalling factors. Indeed, at low concentration the integrity of ROS production is essential for regulation of important cellular features, while aberrant and unregulated ROS accumulation may lead to pathologic permanent change in signal transduction. At this regard, interestingly, monocytes from patients with SSc constitutively release large amounts of O 2 •− and H 2 O 2 in vitro through the Nox pathway (27) . In particular in SSc fibroblasts has been demonstrated the persistent activation of intracellular Ha-Ras/ERK1-2/Nox loop (28, 29) . But, if this is so, which factors are able to trigger and maintain the machinery involved in ROS generation in SSc? In an elegant study has been provided the evidence that sera of SSc patients invariably show stimulatory antibodies to PDGF receptor. The interaction ligand-receptor at the cellular surface turn on the Ras/Nox/ERK1-2 pathway which lead to pro-fibrotic gene expression (3) (Fig. 2) . Taken collectively these data help to clarify the pathogenic puzzle of SSc, highlighting the hypothesis that OS may be the missing link between humoral immunity activation and fibrotic process.
Asymmetric dimethylarginine (ADMA) and OS in SSc
Several reports have recently pointed out the role of (ADMA), an endogenous inhibitor of nitric oxide synthase, in promoting endothelial dysfunction (30) . An increase of plasma ADMA levels has been reported in patients affected by SSc (31) and it has been supposed that ADMA would affect arteriolar tone by reducing nitric oxide (NO) availability. Moreover, has been demonstrated a significant association between raised ADMA levels and increased endothelial permeability (32), impaired progenitor endothelial cells reserve (33) and defective angiogenesis (34) , all of them are critical steps in the development and progression of SSc. Very recently in an experimental model has also been proven that exogenous ADMA elicits vascular diameter reduction by increasing Nox-related ROS production (35) . Moreover, ROS accumulation seems to promote ADMA elevation reducing the activity of the ADMA demethylating enzyme physiologically involved in its catabolism (36) . Furthermore, a convincing proof of the redox sensitive regulation of ADMA metabolism comes from the observation that antioxidant treatment is able to reduce plasma ADMA levels (37) . In synthesis, the interrelation between ADMA/NO pathway and ROS production is well accepted. Therefore it is conceivable that an increase of OS would be the link between ADMA elevation and endothelial dysfunction in SSc.
Isoprostanes and SSc
Lipid peroxidation occurs as a part of the oxidant injury, involves several substrates and leads to highly reactive intermediates formation (Fig. 1) . Among them are isoprostanes, a family of eicosanoids produced predominantly by free radical oxidation of arachidonic acid esterified to phospholipids (38) (Fig. 1) . Therefore, determination of F 2 -isoprostanes levels (in particular of 8-isoPGF 2 ) is currently considered one of the best available tool to assess OS level in vivo (39) . Moreover, isoprostanes are more than inert markers of oxidative burden: they are proven to induce ROS production (40) , to mediate vascular constriction (41, 42), endothelin-1 gene expression (43) and fibroblast proliferation (44) and to impair angiogenesis (45) , all of them are well known specific features of SSc. Thus, is not surprising that raised isoprostanes levels have been demonstrated in different organic fluids (46) (47) (48) (49) (50) in SSc and are related to severity and extent of visceral (49) and vascular involvement (49, 51) . Of interest such an increase of F 2 -isoprostanes seems predominate in the early steps of SSc (50) highlighting the role of OS as a key factor in the induction of disease.
Clinical and experimental evidences of antioxidative effect of Iloprost
If we look back to the field of prostacyclin and oxidative stress we find several clinical and experimental data about the potential role of Iloprost both in reducing ROS amount and in strength scavenger system efficiency.
In two seminal papers a reversible and dose-related inhibition of the O 2 •− production (by neutrophils) was demonstrated in animal models of ischemic myocardium damage in the presence of Iloprost (52, 53) . In addition, Iloprost has proven to significantly decrease MDA in animal models of abdominal aortic ischemia-reperfusion (54) and induced liver peroxidation (55) (59) . Urinary 8-isoPGF 2α levels were measured before and after a five days infusional cycle of iloprost (0.5-2 ng/kg/min, mean dose 1.3 ng/kg/min) in twenty eight SSc patients. Post-infusional urinary 8-isoPGF 2α levels appeared significantly reduced respect to basal levels in SSc patients but they remained elevated compared to control subjects. Of interest from a clinical point of view, a more significant decline in 8-isoPGF 2α levels was demonstrated in the early phases (disease duration <5 yrs) and in the limited subset of disease suggesting that the antioxidant activity of Iloprost is most likely to be effective early in the course of SSc. This finding may be of considerable interest since it would also help to explain the failure of antioxidant therapy in clinical trials in SSc, suggesting that the treatment was administered too late in the course of disease. The results of our study agree well with earlier report which show a reduction of isoprostanes in patients with primary pulmonary arterial hypertension receiving epoprostenol, a synthetic salt of prostacyclin (60) . Iloprost activity in preserving scavenging system has also reported to positively affect hearth transplantation in an animal model when added to cardioplegic solutions, by maintaining levels of GSH and CAT in transplanted organ (61) . Similarly pretreatment of isolated hearts with Iloprost improved myocardial GSH/GSSG ratio and SOD levels in ischemia-reperfusion injury (62) and myocardial infarction (63, 64) . Iloprost potential in restoring antioxidant reserve (CAT and SOD levels) was also provided in vivo, in patients affected by SSc: the authors also propose that this effect on inner antioxidant capacity can explain the long-term effect of Iloprost instead of its very short half-life time (57). A reduction of ADMA level, and by inference, of OS is expected to have therapeutic implications in vascular disease. Very recently Iloprost has shown to reduce ADMA levels in patients with Büerger disease (65) . On the basis of the above reported tight correlation between ADMA and OS, this observation would support that Iloprost antioxidant properties might be the indirect consequence of a beneficial regulation of ADMA/NO pathway. Taken together these findings support the assumption that treatment with prostacyclin analogs in vivo would carry a singular and clinically meaningful effect in balancing OS.
Putative pathways of OS reduction by Iloprost
Despite the fact that a substantial amount of literature is available on the antioxidant effect of Iloprost, the mechanisms behind it are less clear. Prostanoids are derivative of arachidonic acid and they possess multiple and even opposing effects, the most known being the regulation of vascular homeostasis. Among these compounds TXA 2 induces vasoconstriction and platelet aggregation, while prostacyclin (PGI 2 ) is a potent vasodilator and antiaggregant agent. PGI 2 signals through a single G-protein-coupled receptor (IP) (66), increasing intracellular cAMP in several cellular types. Iloprost is a long lasting synthetic analog of PGI 2 of which it mimics physiologic activities interacting with the prostacyclin (IP) receptor (67) . One of the most consistent features of scleroderma is the excessive vasoconstriction in response to stimuli, such as cold exposure, often followed by excessive reactive hyperaemia on rewarming. Such an condition, termed Raynaud's phenomenon, leads to harmful ischemia-reperfusion injury, obviously in peripheral tissue but also in internal organs. A significant burst of ROS generation in this hypoxic milieu occurs as a consequence of adenosine triphosphate depletion. This latter event is rapidly followed by different calcium channels opening and increase of cytosolic Ca 2+ which in turn enhances the PKc/RAS/Nox pathway ( Fig. 2) (68) . In addition, as previously stated, hypoxia powerfully upregulates Nox expression contributing to ROS generation. Therefore, the reduction of vasospastic propensity gained with Iloprost infusions would indirectly lower intracellular ROS accumulation via both the reduction of cytosolic Ca 2+ overload and the tyrosin kinases receptor MAPK pathway inhibition. In support of this mechanism, treatment with prostacyclin analogues of cultured rat hepatocytes exposed to superoxide demonstrated cytoprotection via an increase in intracellular cAMP and a decrease in free intracellular calcium levels (69) . Alternatively, has been showed that an improvement in perfusion would be exert a beneficial effect on the level of antioxidant system and a reduction in free catalyzed lipid peroxidation (57) . Nonetheless it is known that OS is a chronic condition in SSc depending just in a minimal manner from transient vasospastic attack (70) . Moreover, the major question whether ROS generation is an upstream signal respect to hypoxic injury or conversely its consequence has not clearly solved so far (71) . Considering these pros and cons the "anti-ischemic" effect of Iloprost is unlikely to greatly account for the stable reduction of "oxidant assaults". More interestingly, as above stated, the machinery accounting for ROS production appears constitutively activated in SSc fibroblasts regardless from physiologic stimulation (3, 28) and may be the main source of OS in SSc. Thus disruption of vicious circuitry leading to Nox activation may have the potential to reduce OS and minimize its deleterious effect in activating proliferative and profibrotic signals. At this regard, Muzzafar et al. provided a series of unequivocal evidences that Iloprost is able to reduce the activity and expression of NOX in vascular cells: the Rac and p47phox activation and translocation to the plasma membrane, an essential step for Nox functionality, appear inhibited in vitro by cAMP-protein-kinase-A (PKA) axis after incubation with Iloprost (24, 72, 73) . Similarly has been clearly demonstrated in an in vitro model that Iloprost reduce profibrotic effect of PDGF by inhibiting the Ras/ERK1-2 pathway trough the cAMP-protein-kinase-A (PKa) axis. In particular was proven that Iloprost is able to inhibit ERK phosphorilation and that this effect can be abolished by PKa inhibitor. (74, 75) (Fig. 2) .
Therefore, trough suppression of Nox expression and subsequent ROS accumulation, Iloprost would directly reduce OS related tissue damage and profibrotic intracellular signalling. These observations further support the hypothesis that OS is deeply implicated in the induction of profibrotic phenotype of SS.
CONCLUDING REMARKS
OS is linked to SSc in a fashion so intricate that at present the question whether it is a culprit or a downstream consequence of vasculopathy and tissue injury is far to be convincingly answered. Nonetheless, there are little doubts that OS is primarily and early involved in the pathogenesis of disease suggesting that targeting OS may potentially reduce the severity of clinical features. However, despite the efforts yet the most compelling evidence of this assumption (inhibition/reduction of tissue injury by antioxidant therapy) has not been clearly provided. At this regard, it would be of interest for the management of SSc to obtain more convincing proof about the antioxidant activity of Iloprost and to clarify the dimension of its relative contribution to the beneficial effects of this therapy. Thus, further trials that will be performed to evaluate this issue should be specifically aimed to explore the following points: I. confirm in vivo the effect of Iloprost on OS and quantify the clinical benefits in terms of tissue damage and prognostic impact. II. evaluate the presence of a medium/long-term effect, beyond the brief space of the infusional cycle. III. further clarify the potentially involved molecular pathways
